key: cord-0934952-2zvayfsg
authors: Sheriff, Tabrez; Dickenson-Panas, Helen; Murrell, Dédée F.
title: Conducting dermatology clinical trials during the COVID-19 pandemic
date: 2020-12-16
journal: Clin Dermatol
DOI: 10.1016/j.clindermatol.2020.12.019
sha: d4f3db70c8476e592ec3fe89d955a22898495128
doc_id: 934952
cord_uid: 2zvayfsg

The clinical trials industry faces a number of challenges during the evolving coronavirus disease 2019 (COVID-19) pandemic, for example, site closures, mandatory self-isolation, travel restrictions, interruptions to delivery of investigational product, or staff or participants becoming infected with severe acute respiratory syndrome coronavirus 2. These challenges can pose difficulties in adhering to visit schedules, performing laboratory testing, conducting protocol-specified procedures, and administration of investigational product. As a result, clinical trial sites, contract research organizations, and sponsors have had to act swiftly to ensure that trial patients are safe and systems are in place for continuing trials. Protocols should also be amended to reflect changes and approved by an ethics board. The authors provide practical considerations and recommendations for dermatology clinical trial operations during the COVID-19 pandemic.

The rapid spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has demanded prompt response to the conduct of clinical trials. Guidance should be sought from governing health bodies such as the U.S. Food and Drug Administration (FDA), European Medicines Agency, or Therapeutics Goods Administration (TGA), in line with local coronavirus disease 2019 (COVID-19) governmental policies. 1 Sponsors should work with principal investigators and site staff to ensure patient safety. We provide practical considerations for conducting clinical trials during the COVID-19 pandemic.

1. Priority: Assessing the risks and benefits of continuing the trial in the existing form, modified form, or discontinuing the trial on patient safety and well-being 2. Participation: Ability of the participant, based on individual patient risk factors and in accordance with the trial protocol, to participate in the trial without compromising the validity or integrity of the trial 3. Capacity: Assessment of resources available for continuing the trial, including site staff, support staff (contract research organization [CRO] and medical moni-T. Sheriff et al.

JID: CID [mNS; January 5, 2021; 15:48 ] tors availability), couriers, and equipment and investigational product (IP) supply 2

Contingency planning is an ongoing process as new information surrounding the virus surfaces. Institutional Review Board (IRB) guidelines and local COVID-19 guidelines should be followed wherever possible for guidance. Ethics approval is essential if any protocol amendments or additions are made that often requires extensive consultation with study sites before submission to an ethics board.

Recruitment of new participants should be minimized to reduce infection risk and transmission unless the trial reduces mortality, improves the prognosis of a debilitating condition (eg, severe inflammatory dermatosis, advanced/high-grade cutaneous malignancy, or autoimmune blistering diseases), or where conventional therapy causes greater harm than the IP. Many sponsors have also paused recruitment of new participants into open label extension (OLE) phases and allowing only existing patients who have shown adequate safety to enroll; furthermore, many public hospital facilities that share clinic areas have closed many trials.

The following steps were taken at our private facility with respect to minimizing SARS-CoV-2 infection risk:

• Re-educating staff on the importance of regular handwashing and use of hand sanitizer between patients • Increased hygiene measures such as making hand sanitizers and tissues available to patients • Instructing the daily professional cleaner to carry out extra sanitizing measures such as daily disinfecting of all chairs, telephones, door handles, and all other surfaces • Staff sanitizing rooms between patients including spraying the rooms with disinfectant spray and wiping down door handles with alcohol-based sanitizer. • Mandatory wearing of surgical masks for all staff and participants during trial visits • Staggering appointments to reduce the number of patients in the waiting room • Reducing the number of chairs in the waiting room to increase the distance between patients • Allowing patients to bring in their own shorts and singlets or suitable dresses to wear for skin examinations (on-site shorts and singlets are fully laundered after every use) • Instructing patients to reschedule appointments if they have coryzal clinical manifestations or if they have travelled overseas in the past 14 days • Minimizing nonessential personnel on site such as medical students, pharmaceutical company representatives, and additional family members who are not primary careers

Should the situation arise that a member of staff is exposed to COVID-19 that staff member should not be allowed on site until a 14-day self-isolation period is completed. If the staff member has tested positive to COVID-19, then that staff member should not be allowed to return to the site until they return two consecutive negative tests and a clearance certificate from a medical practitioner is presented. It is recommended that clinical trial sites adopt a policy of having backup subinvestigators, backup unblinded team members, and a backup study coordinator for all clinical trials, to ensure that the site can remain operational for an extended period without disruption should a member of staff be required to self-isolate.

In the case of all staff being exposed and self-isolation is required, the site should inform participants, in particular any exposed participants, and all sponsors and clinical research associates (CRAs) of the situation. All staff should be given the capability to work remotely from home in order for the administrative side of clinical trials to continue. Once the site is cleared to recommence operations, all patients, sponsors, and CRAs should be notified.

In the case of a forced lockdown by the government, site should inform patients, sponsors, and CRAs of the situation.

As above, all staff should be given the capability to work remotely from home in order for the administrative side of clinical trials to continue. Once the site is cleared to recommence operations all patients, sponsors and CRAs should be notified.

Trial participants should be informed promptly of any protocol-related changes. If approved by the sponsor, visits should ideally transition to remote teledermatology visits, particularly for higher-risk individuals. Higher-risk individuals are those above 80 years of age, receiving chemotherapy, having multiple cardiac and respiratory comorbidities, and working in high-risk environments. 3 The advice given to our participants is in line with the Australian government COVID-19 guidelines and the National Health and Medical Research Council (NHMRC).

The following measures were taken at our facility to ensure participant transparency:

• All existing clinical trial participants received a telephone call from the lead subinvestigator of the clinical trial they are participating in. The subinvestigators informed participants that the trial site is still fully operational and able to continue seeing patients for clinical trial visits.

• Participants have been informed of the above measures to reassure them that the site has taken precautions to ensure their safety. • Participants have been advised that, if they prefer, subinvestigators can meet them at the staff entrance and then escort them straight into a consultation room so as to minimize their contact with other staff and patients in the building. • If approved by the sponsor, participants in certain studies have been advised of the possibility of remote study visits in conjunction with a pre-approved courier delivering additional supplies of study drug to the patient's home. • Participants have been given the opportunity to ask questions and discuss any concerns they may have regarding their participation in a clinical trial, the study drug, and SARS-CoV-2. 4 All information provided to participants is based on what the site has been provided by sponsors and CRAs. • Every participant was given a study card with emergency contact numbers if they contracting SARS-CoV-2. • All conversations with participants have been documented in the patient's file and in the study source notes.

Overall decisions will be guided by participant safety, the ethics approved clinical trial protocol, and the requirements of the sponsor.

Teledermatology remote visits are being approved for many trials via privacy-compliant platforms (eg, Microsoft Teams and Zoom). Many dermatologic assessments, such as Severity of Alopecia Tool Score (SALT), Pemphigus Disease Activity Index (PDAI) score, and Eczema Area and Severity Index (EASI), can be performed with high-resolution emailed photographs. Only strictly necessary trial procedures should be conducted remotely. 5 Adverse events and concomitant medications should be recorded as a bare minimum.

For clinical trials where remote visits are possible, couriers should be arranged for IP to be mailed to the participant's residence. Courier companies that can maintain patient confidentiality are available. Where IP needs to be administered on site, community nursing services may be employed for IP administration and other essential duties only. Local laboratories may also be used instead of central laboratories to minimize infection risk and prevent shipping/courier delays.

During the COVID-19 pandemic measures should be taken to ensure that trial participants are safe and informed, and staff is available at all times. Contingency planning should be conducted in consultation with sponsors to determine continuation, discontinuation, and enrolment of new participants. Several strategies can be implemented to continue dermatology clinical trials, including switching to teledermatology visits, infection control measures, use of local laboratories, and community nursing if possible. The pandemic has also allowed us to reflect on clinical trial processes to better refine them for the future.

Clinical Trial Conduct During the COVID-19 Pandemic

Clinical characteristics of coronavirus disease 2019 in China

Points to consider on implications of coronavirus disease (COVID-19) on methodological aspects of ongoing clinical trials

Guidance on the management of clinical trials during the COVID-19 (coronavirus) pandemic